^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Previse

i
Other names: Previse | Capsulomics
Related tests:
Evidence

News

1m
Previse Showcases New Data Highlighting Clinical Utility of Esopredict® Barrett's Esophagus Prognostic Test at ACG 2024 (Previse Press Release)
"Previse...today announced the company presented prospective real-world clinical utility data for Esopredict at the 2024 American College of Gastroenterology Annual Scientific Meeting (ACG) being held October 25-30 in Philadelphia, PA and virtually."
Clinical data
|
Esopredict™ test
2ms
Previse awarded $1.8M NIH grant to develop esophageal cancer test (Genomeweb)
"Gastrointestinal health firm Previse said Tuesday that it has been awarded a $1.8 million grant from the National Institutes of Health for the development and commercialization of an esophageal cancer screening test."
Grant
4ms
The American Journal of Gastroenterology publishes esopredict performance results from pivotal clinical validation study (PRNewswire)
"Previse..announced today that its clinical validation study results for its flagship assay, Esopredict, were published in the American Journal of Gastroenterology (AJG). The publication, "Validation of an Epigenetic Prognostic Assay to Accurately Risk Stratify Patients with Barrett's Esophagus," highlights Esopredict, a first-in-class DNA methylation test for identifying patients with precancerous Barrett's esophagus (BE) who are likely to progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in the future."
Clinical
|
Esopredict™ test
1year
Previse wins $1.8M NIH grant to help advance esophageal cancer risk PCR test (Genomeweb)
"Previse said on Thursday that it has been awarded a $1.8 million grant from the National Institutes of Health to support additional clinical testing of Esopredict, the company's recently launched laboratory-developed real-time PCR test for esophageal cancer risk."
Grant
|
Esopredict™ test
over1year
Previse presents data from two studies at Digestive Disease Week 2023 on new tests to detect risk of esophageal cancer (Previse Press Release)
"Previse...announced details on Monday, May 8, of two studies presented during Digestive Disease Week® 2023, held May 6-9 in Chicago. Both analyses clinically validate use of biomarkers to detect and assess risk of esophageal cancer developing in patients with Barrett’s esophagus."
Clinical data
|
Esopredict™ test
over1year
PREVISE CLOSES $3M SEED TO TACKLE EARLY CANCER DETECTION AND LAUNCHES COMPANY’S FIRST ESOPHAGEAL CANCER PROGNOSTIC TEST (PRNewswire)
"Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™....In addition to launching Esopredict™, Previse also raised a $3M seed round, with participation from TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and numerous angel investors."
Financing • Launch
|
Esopredict™ test